Bristol-Myers Squibb’s planned $74-billion purchase of Celgene has hit a significant obstacle after its largest institutional shareholder said it did not back the deal.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.